FRENCH healthcare company Sanofi said it would stop further work on amcenestrant, once seen to have large potential against breast cancer, after a second trial failure dealt a major blow to its drug development prospects.The move puts more pressure on Sanofi to bolster its drug development pipeline as it grows increasingly dependent on its multi-billion best seller, exzecma and asthma treatment Dupixent, and after it fell far behind in the race to develop COVID-19 vaccines.A trial dubbed AMEERA-5, which was testing amcenestrant on women with newly-diagnosed advanced breast cancer, was stopped early because an independent monitoring panel found no signs of it working.“All other studies of amc
Hence then, the article about sanofi trial failure ends development of breast cancer treatment amcenestrant was published today ( ) and is available onDaily Sun ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Sanofi trial failure ends development of breast cancer treatment amcenestrant )